Overview

Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Status:
Not yet recruiting

Trial end date:
2023-07-30

Target enrollment:

Participant gender:

Summary

This is a Phase II, multi-center pilot study assessing the efficacy and safety of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligo-metastatic non-small cell lung cancer (NSCLC).

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Treatments:

Antibodies, Monoclonal
Durvalumab